Literature DB >> 11818489

Potential new therapies for the treatment of HIV-1 infection.

Jon H Condra1, Michael D Miller, Daria J Hazuda, Emilio A Emini.   

Abstract

The development and clinical use of chemotherapeutic agents for the treatment of persistent HIV-1 infection over the past decade has profoundly and favorably affected the course of HIV-1 disease for many infected individuals. Unfortunately, the long-term use of these therapies is complicated by unwanted metabolic side effects, by issues of adherence, and by the selection of viral variants with reduced susceptibility. These complications have spurred the search for new anti-HIV-1 agents having improved pharmacological properties and expressing activity against viral variants resistant to the currently available agents. This brief review describes the current state of this search as well as potentially novel viral targets for chemotherapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11818489     DOI: 10.1146/annurev.med.53.082901.104110

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  6 in total

Review 1.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Structure of the HIV-1 frameshift site RNA bound to a small molecule inhibitor of viral replication.

Authors:  Ryan J Marcheschi; Marco Tonelli; Arvind Kumar; Samuel E Butcher
Journal:  ACS Chem Biol       Date:  2011-06-15       Impact factor: 5.100

3.  RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication.

Authors:  Rama M Surabhi; Richard B Gaynor
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  The lupane-type triterpene 30-oxo-calenduladiol is a CCR5 antagonist with anti-HIV-1 and anti-chemotactic activities.

Authors:  Jonathan Barroso-González; Nabil El Jaber-Vazdekis; Laura García-Expósito; José-David Machado; Rafael Zárate; Angel G Ravelo; Ana Estévez-Braun; Agustín Valenzuela-Fernández
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

5.  Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.

Authors:  Hector R Rangel; Jan Weber; Bikram Chakraborty; Arantxa Gutierrez; Michael L Marotta; Muneer Mirza; Patti Kiser; Miguel A Martinez; Jose A Este; Miguel E Quiñones-Mateu
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

6.  Specificity of interaction of INI1/hSNF5 with retroviral integrases and its functional significance.

Authors:  Eric Yung; Masha Sorin; Emilie-Jeanne Wang; Seena Perumal; David Ott; Ganjam V Kalpana
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.